MedTrace Logo

Sitagliptin Treatment in Patients With Type 2 DM After Kidney Transplant

NCT00466518 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-04-07

No results posted yet for this study

Summary

This study is designed to look at the effect sitagliptin has on tacrolimus and sirolimus drug levels in kidney transplant patients. It is also designed to look at the side effects experienced in the transplant population.

Conditions

Interventions

DRUG

Administration of sitagliptin

Sitagliptin 100 mg daily for 3 months

Sponsors & Collaborators

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • James T Lane, MD · University of Nebraska

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466518 on ClinicalTrials.gov